Clinical Trial Search

Primary: Number of Full Analysis Set Participants Who Received HCV Anti-viral Therapy With Sustained Virological Response (SVR) — 4; 4 participants — p=0.01

Primary: Mean Asthma Symptom Score — 2.3; 2.1 Asthma symptom score

Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24 — -16.70; -54.50 percent change — p=<0.0001

Primary: Number of Participants With Undetectable Cancer on MRI-guided Biopsy of Ablation Zone Following Treatment — 26 Participants

Primary: Selective Reminding Test (SRT) — 33.61; 36.23; 36.81; 37.13 Words

Primary: Aggregate Sedative Exposure During PCS Use (up to 5 Days). — 4; 3.5 units on a scale

Primary: Change From Baseline in Lactate Dehydrogenase — 1845.1; 398.7; -1446.4 Units/Liter — p=<0.0001

Primary: Visual Acuity — -0.05; -0.05; -0.05; -0.04 logMAR

Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 — 0.0847; 0.0921; 0.0111 liters — p=0.0002

Primary: Change From Baseline in the Glycosylated Hemoglobin (HbA1c) at 12 Weeks — -0.457; -0.561; -0.428; -0.183 percentage of glycosylated hemoglobin

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths. — 48; 50; 44; 49 Participants

Primary: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab — 32.9; 59.5; 69.3; 71.6 microgram per milliliter (µg/mL)

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation — 43; 46; 46; 1 Participants

Primary: Pain Rating — 5.7 units on a scale

Primary: Number Participants With Adverse Events — 11; 3 Participants